While the CD4+/CD8+ value as a estimation of overall immunity status is still being debated (with some literatures suggesting lower CD4+/CD8+ values representing better immunity27, and other literatures suggesting the contrary28), our results indicated that a lower CD4+/CD8+ value may represent a better overall immunity status in this tumor bearing and CTX chemotherapy setting. The gene discussed is CD8A; the disease is neoplasm.